Please login to the form below

Not currently logged in
Email:
Password:

olaparib

This page shows the latest olaparib news and features for those working in and with pharma, biotech and healthcare.

AZ and MSD surpass rivals with updated Lynparza data

AZ and MSD surpass rivals with updated Lynparza data

AstraZeneca’s (AZ) and Merck Sharp &Dohme’s (MSD) push for first-line setting for its revamped PARP inhibitor Lynparza (olaparib) has been bolstered by some positive phase III data.

Latest news

More from news
Approximately 11 fully matching, plus 50 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics